ClinicalTrials.gg
RecruitingNCT01212354EscaloxUpdated Feb 9, 2016

Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT

A Phase 3 interventional study of Radiotherapy in Locally Advanced Head and Neck Cancer, sponsored by Technical University of Munich. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-02-09.

Sponsored by Technical University of Munich · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Head and Neck Neoplasms with a site in Germany — 26 open to participants now, 38 under way, 9 of them phase 3. Head and Neck Neoplasms · Germany.

Planned enrollment
37th of 98
270 · median 167
Started
2015
with 9 others
Phase 3
26 of 114
3 open now
Primary completion
2025-01
later than 10 of 37 live
Registered
23rd of 114
by date

Among the 114 studies in Head and Neck Neoplasms with a site in Germany, this one is the 37th largest by planned enrollment of the 98 interventional ones that give a count, is one of 10 that started in 2015, is one of 26 in phase 3, reaches primary completion later than 10 of the 37 other live ones, and was the 23rd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

26 of the 114 studies in Head and Neck Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Head and Neck Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The major clinical problem and predominant cause of death after radio-oncological treatment of H+N cancers are loco-regional relapses. This randomized trial tests the hypothesis that dose escalated Intensity Modulated Radiotherapy (IMRT) selectively applied to the macroscopic primary tumor and involved neck nodes - which both in 80% - are hypoxic improves loco-regional control by at least 15% at 2 years. IMRT is combined with concurrent Cis-Platin chemotherapy. Tumor volume which correlates with number of malignant cells as well as tumor hypoxia are important biological parameters which increase radio-resistance, failure of local control and tumor progression. Basing on data of experimental and clinical radiation oncology we consider hypoxia as a useful parameter for pre-therapeutic strati-fication in future randomized radio-chemotherapy trials.

In addition, hypoxia imaging by PET can be used for testing the significance of selective dose escalation on hypoxic tumor sub-volumes ("Dose Painting").

As a prerequisite for such innovative studies addressing hypoxia the translational part investigates the following key issues: correlation between the size of total tumor volume (primary, lymph nodes) and hypoxic sub-volume, the spatial shift of the hypoxic sub-volume before start of treatment and the correlation of loco-regional control and hypoxia.

Before starting the main study a pre-study to assess the occurrence of radiation induced toxicities is mandatory to be performed. In a step-wise dose-escalation in a cohort-design the safety of dose-escalation should be determined. Step one: 6 patients Step two: 14 patients. In the pre-study the 1st group (6 patients) should be treated with 2.2 Gy up to 77.0 Gy for DEVPT and DEVLK. After evaluation of the toxicity the next 14 patients should be treated by this scheme.

Read the detailed description

The pre-study with sequential design is a prospective multicentre interventional pilot study to assess toxicity of intensity modulated radiotherapy (IMRT) plus Cisplatin of head and neck cancers

The main study is a multicenter phase III randomized trial on the effect of dose escalated radiotherapy with concomitant chemotherapy to treat local advanced head and neck cancer. The study compares two treatment arms:

Experimental intervention (group A): 7 weeks standard radio-chemotherapy with 20 mg/m²/d Cisplatin in week 1 and 5 including simultaneous radiation dose escalation (5x2.3 Gy per week up to 80.5 Gy total dose) to the primary tumour and involved neck nodes ≥ 2 cm.

The Dose Escalated tumour Volume (DEVPT) is defined by the macroscopic (Gross) primary Tumour Volume (GTVPT) minus a 3 mm margin at organs at risk or at mucosal sites to reduce the risk of high dose deposition at the surrounding normal tissue. All involved lymph nodes visualized by CT with a minimal diameter of 2 cm are also included for dose escalation (DEVLN). The DEVLN of the lymph nodes > 2 cm is determined by the involved lymph node volume (GTVLN) minus a margin of 3 mm at organs at risk or mucosal sites. The 3 mm margin as well as the part of the target volume with suspected microscopic tumor extension receives 2 Gy per fraction.

Control intervention (group B): 7 weeks standard radio-chemotherapy with 5x2.0 Gy per week up to a total dose of 70 Gy and 20 mg/m²/d Cisplatin in week 1 and 5.

In group A and B: The treatment of the elective cervical lymphatic areas is given in the same session as the GTV but with a single dose of 1.6 Gy up to 56 Gy (so called simultaneous integrated boost concept).

03

Conditions studied

  • Locally Advanced Head and Neck Cancer

Keywords

  • intensity modulated radiotherapy
  • selective dose escalation
  • hypoxia
  • head cancer
  • neck cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Age ≥ 18 ≤ 70 years
  • Independent of gender
  • Independent of race
  • 0 - 2
  • Tumor of oral cavity, oropharynx or hypopharynx
  • Histology: squamous cell carcinoma
  • Curative treatment intended
  • Tumor is classified as irresectable (see Appendix)
  • Woman of child-bearing age: negative pregnancy test in serum
  • in male and female patients and their partners if of , willingness to use effective contraceptive method for the study duration and 2 months post therapy
  • Sufficient bone marrow reserves during 7 days before study inclusion; (leukocytes ≥ 4 x 109/l, absolute no. of neutrophiles (ANC) ≥ 2 x 109/; count ≥ 100 x 109/l; ≥ 10g/dl)
  • adequate liver function during 7 days before study inclusion (total bilirubine ≤ 2,5 x (upper limit of normal), ASAT/ ALAT ≤ 2,5 x ULN, alkaline phosphatase ≤ 2,5 x ULN of the institution's normal value)
  • adequate kidney function during 7 days before study inclusion; serum creatinine ≤ 130 μmol/l; ≥ 70 ml/min
  • all patients should have a dental examination before starting therapy and when necessary be treated, adaptation of a teeth protection bar
  • a percutane feeding tube should be applied before start of treatment

Exclusion criteria

Exclusion Criteria:

  • Infiltration of the mandible and / or larynx
  • impaired renal and/ or liver function
  • secondary , unknown primary cancer, nasopharynx cancer or salivary gland cancers
  • disease
  • Another cancer within 5 years of study entry
  • Serious concomitant disease or medical condition
  • Pregnancy or lactation
  • Women of with unclear (post menopausal women must have been amenorrheal for at least 12 months to be considered of non-childbearing potential)
  • previous treatment with chemotherapy, radiotherapy or surgery in head and neck (except an excisional or biopsy for histology)
  • concurrent treatment with other experimental drugs or participation in another clinical trial with any drug within 30 days prior to study screening
  • of \< 12 months
  • to receive Cisplatin
  • social situations that limit compliance with study requirements
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    A - experimental

    7 weeks Radiotherapy Intervention with with 5x2.3 Gy per week up to a total dose of 80.5 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.

    Radiation: Radiotherapy

  • Active comparator
    B - control

    7 weeks Radiotherapy Intervention with 5x2.0 Gy per week up to a total dose of 70 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.

    Radiation: Radiotherapy

Interventions

  • RadiationRadiotherapy

    7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)

    Also known as: IMRT-SIB

06

What researchers measure

Primary outcomes

  1. 2 year-loco-regional control

    Time frame: 2 years

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: 2 years

  2. Progression-free survival (PFS)

    Time frame: 2 years

  3. Time to progression (TTP)

    Time frame: 5 years

  4. Distant metastases (DM)

    Time frame: 2 years

  5. Acute and late toxicity esp. concerning salivary glands

    Time frame: 5 years

  6. Quality of life (EORTC QoL-C30, H&N 35)

    Time frame: 2 years

  7. Adverse effects according to NCI CTC-AE (VERSION 4.0/ 10/1/2010) and LENT-SOMA

    Time frame: 2 years

  8. FMISO PET/CT: Reproducibility and correlation with treatment coutcome

    Time frame: 2 years

  9. Relapse free Survival (RFS)

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Klinik für RadioOnkologie Strahlentherapie
    Munich, Bavaria 81675, Germany
    Recruiting
    • Steffi U. Pigorsch, Dr. med. · Contactsteffi.pigorsch@lrz.tum.de · +49 (0)89-4140
    • Sabine Barta, Dr. · Contactsabine.barta@mri.tum.de · +49 (0)89-4140
    • Steffi U. Pigorsch, Dr. med. · Principal investigator
    • Stephanie Combs, Prof. Dr. · Sub investigator
08

References and documents

Publications

  • Pigorsch SU, Kampfer S, Oechsner M, Mayinger MC, Mozes P, Devecka M, Kessel KK, Combs SE, Wilkens JJ. Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study. Radiat Oncol. 2020 Nov 2;15(1):253. doi: 10.1186/s13014-020-01693-2. PubMed 33138837 ↗
  • Pigorsch SU, Wilkens JJ, Kampfer S, Kehl V, Hapfelmeier A, Schlager C, Bier H, Schwaiger M, Combs SE. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. Radiat Oncol. 2017 Mar 1;12(1):45. doi: 10.1186/s13014-017-0776-1. PubMed 28249612 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jan 2025 and a completion of Sep 2025. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2010
First posted
Sep 30, 2010
Start
Jul 2015
Primary completionEst.
Jan 2025
CompletionEst.
Sep 2025
Last update
Feb 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01212354
Responsible party
Sponsor
First posted
Sep 30, 2010
Start date
Jul 2015
Primary completion
Jan 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Feb 9, 2016

Study contacts

Sabine Barta, Dr.
Contact
sabine.barta@mri.tum.de
+49 (0)89-4140 ext. 7787
Steffi U. Pigorsch, Dr. med.
principal investigator · Klinik für Strahlentherapie und Radiologische Onkologie, Klinikum rechts der Isar der TU München Ismaningerstr. 22; 81675 Munich, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion